Lymphoma Clinical Trials & Research

Lymphoma Clinical Trials & Research

Share
Print
Share
Print

Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.

The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.

Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.


Burkitt’s Lymphoma
Chronic Lymphocytic Lymphoma (CLL)
Diffuse Large B-Cell Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

A Phase III Study of Acalabrutinib plus R-CHOP Therapy in Patients 65 and Younger with Previously Untreated Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 21-141]

A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 21-164]

A Phase II/III Study of CC-486 (Oral Azacitidine) plus Standard Therapy in Older Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Colette N. Owens
[Protocol 21-210]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of REGN3767 and/or REGN2810 Immunotherapy in Patients with Advanced Lymphoma
M. Lia Palomba
[Protocol 17-421]

A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]

A Phase III Study of Polatuzumab Vedotin Combined with Rituximab, Gemcitabine, and Oxaliplatin in People with Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 20-031]

A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]

A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]

A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 21-164]

A Phase II Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide Before Stem Cell Transplantation in People with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 21-208]

Follicular Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 21-164]

A Phase II/III Study of CC-486 (Oral Azacitidine) plus Standard Therapy in Older Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Colette N. Owens
[Protocol 21-210]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 16-1614]

A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]

A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

A Phase II Study of ME-401 in People with Recurrent or Persistent Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 19-246]

A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]

A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]

A Phase IB/III Study of Lenalidomide and Rituximab plus Tazemetostat or Placebo in Patients with Recurrent or Persistent Follicular Lymphoma
Connie Lee Batlevi
[Protocol 20-252]

A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]

A Phase I Study of Glofitamab Alone or in Combination with Obinutuzumab in People with Recurrent or Persistent Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 20-569]

A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 21-164]

HIV+ Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Andrew D. Zelenetz
[Protocol 18-427]

A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 16-1614]

A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]

A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]

A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]

A Phase I Study of Glofitamab Alone or in Combination with Obinutuzumab in People with Recurrent or Persistent Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 20-569]

Marginal Zone Lymphoma
Mediastinal Grey Zone Lymphoma
Small Lymphocytic Lymphoma (SLL)
T-cell Lymphoma: PTCL, CTCL and Extra-nodal NK nasal type

Newly Diagnosed/Frontline Studies and Advanced Disease

A Pilot Study of Pembrolizumab Immunotherapy in Patients with Extranodal NK/T-cell Nasal-Type Lymphoma
Alison J. Moskowitz
[Protocol 18-393] NK nasal type only

Prior Treatment (Relapsed/Refractory)

A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042] PTCL only

A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Niloufer Khan
[Protocol 18-147] CTCL only

A Phase I Study of TTI-621 Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347] CTCL only

PTCL only

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210] CTCL only

A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297] PTCL only

A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535] CTCL and PTCL

A Phase IB/II Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab to Treat Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 21-128] CTCL only

A Phase I Study of Ruxolitinib and Duvelisib to Treat Recurrent or Persistent T-Cell or NK-Cell Lymphomas
Alison J. Moskowitz
[Protocol 21-176] CTCL, PTCL, and MK nasal type

A Phase II Study of AFM13 in People with T-Cell Lymphoma that Has Not Responded to Treatment
Steven M. Horwitz
[Protocol 20-461] CTCL and PTCL

A Phase I Study Assessing the Addition of Lenalidomide to the Usual Combination Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma
Steven M. Horwitz
[Protocol 21-140] PTCL only

Waldenstrom’s Macroglobulinemia